Augustine Therapeutics Doses First Patient in CMT Clinical Trial of AGT-100216
Augustine Therapeutics doses the first patient in Phase I trial of AGT-100216, a potential new treatment for CMT.
Promising Results from Govorestat Trial for CMT-SORD Shared at PNS 2025
Applied Therapeutics shares promising 12-month Govorestat trial results for CMT-SORD at PNS 2025.